There are about 100 of them, all members of the Health and Law association, and they filed a lawsuit against the pharmaceutical multinational Bayer after being "victims" of the contraceptive pills Yaz, Yasmin and Yasminelle, marketed by the pharmaceutical multinational.
Thrombosis and emboli
While taking contraceptives (but the pills in question are also often prescribed against acne or to treat hormonal dysfunctions) women have in fact accused episodes of thrombosis, which have led to more or less serious consequences. The most striking case is that of a young woman from Verona who has been in a vegetative coma for ten years (she was 26 when she took the pill).
Class Action in Turin
The complaint, filed on behalf of the Treviso lawyer Sergio Calvetti of the Calvetti & Lawyers law firm in Verona, was filed with the Turin prosecutor's office. The women are asking the multinational for compensation for the damage suffered and the suspension of the distribution of the three medicines, all based on Drospirenone, throughout Europe.
The cases of France and Germany
Numerous precedents against the latest generation pills. In France in 2013, a fuss broke out after the death of two women taking these contraceptives, so much so that in recent years the prescriptions of this type of medicines have dropped by 60%. In Germany, a civil case has been initiated against the pharmaceutical company Bayer by some women who, after taking Yasminelle, had suffered a severe pulmonary embolism.
142 million refunds in the US
“In the United States – reads the website of the Calvetti & Lawyers law firm – the US Food and Drug Administration ordered Bayer to strengthen risk warnings on these products and even fined the German pharmaceutical company for misleading advertising by imposing a $20 million corrective advertising campaign.
Again in the United States, Bayer compensated 651 women who had initiated lawsuits after accusing thromboembolic episodes that had also led to heart attacks and strokes. In all, the drug company said, $142 million in settlement reimbursements were paid out, for an average of about $218,000 in the lawsuit.
Revised leaflets
As for Europe, the EMA - European Medicines Agency - had to address the issue at the instigation of numerous States and the Commission: "following the outcome of in-depth procedures, on the one hand, the results of the most recent scientific studies were confirmed which indicate an increased risk and, on the other, Bayer's request to vary the marketing of these products for the treatment of moderate acne among women, highlighting precisely that the risks (of venous thromboembolism) would have been greater than the benefits”, states the law firm.
Related news: 5 days after pill: disinformation and violation of sales rules
